Modern conceptions of brain function consider the brain as a "predictive organ," where learned regularities about the world are utilised to facilitate perception of incoming sensory input. Critically, this process hinges on a role for cognitive penetrability. We review a mechanism to explain this process and expand our previous proposals of cognitive penetrability in visual recognition to social vision and visual hallucinations.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7392534 | PMC |
| http://dx.doi.org/10.1017/S0140525X15002599 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Investigating long‐term, progressive cerebral microvascular alterations in late‐onset Alzheimer's disease using APOE4 transgenic mice.
Alzheimers Dement
December 2024
Brown University, Providence, RI, USA
Background: Recent studies show apolipoprotein E4 (APOE4), the strongest known genetic risk factor for late‐onset Alzheimer’s disease, is associated with vascular dysfunctions such as blood‐brain barrier breakdown, in both animal models and humans. However, there is a lack of understanding on how vascular alterations progress with age in APOE4.
Method: Human APOE4 (m/f, n=10 per group) and APOE3 targeted replacement mice (m, n=10) were used to investigate temporal dynamics of long‐term, progressive cerebral microvascular alterations in APOE4.
Background: Digital cognitive tools offer novel ways to detect early cognitive changes associated with preclinical Alzheimer’s disease (AD). A digital version of the maze test (dMaze) was recently developed using a digital pen (12 ms temporal precision) to uniquely capture the process of test completion, reflecting the thinking effort, potentially more sensitive to early cognitive deficits in preclinical AD. The sensitivity of these novel digital maze test variables—Wall Penetration Count and Speed Standard Deviation (Speed SD)—to detect early amyloid‐β burden was evaluated, hypothesizing that greater amyloid accumulation would be associated with greater variability of speed, and more wall penetration errors while completing the task, reflecting a greater thinking effort.
View Article and Find Full Text PDFPFTAIRE peptide degrading cyclin Y and ameliorating cognitive deficits in mouse models of Alzheimer’s Disease.
Alzheimers Dement
December 2024
Yonsei University, Incheon, Incheon, Korea, Republic of (South)
Background: Cyclin Y (CCNY) is a member of cyclin protein family inhibiting long‐term synaptic plasticity, which is related to the learning and memory function in neuronal system. Recently, CCNY has been reported to associate with the cognitive deficits in Alzheimer’s disease (AD).
Method: In this study, we discovered PFTAIRE peptide to diminish CCNY protein level and to ameliorate cognitive dysfunction in AD.
Efficacy of a Muscarinic (M1) Positive Allosteric Modulator, SUVN‐I7016031 in Animal Models of Dementia.
Alzheimers Dement
December 2024
Suven Life Sciences, Hyderabad, Telangana, India
Background: SUVN‐I7016031 is a novel and selective positive allosteric modulator (PAM) of the M1 subtype of the muscarinic acetylcholine receptors (mAChRs). The proposed primary indication for SUVN‐I7016031 is in the treatment of dementia such as Alzheimer’s disease dementia (ADD) and Parkinson’s disease dementia (PDD). In the current research, the pharmacological properties of SUVN‐I7016031 in various types of dementia were investigated.
View Article and Find Full Text PDFDiscovery and Characterization Small Molecule Modulators of Striatal‐Enriched Protein Tyrosine Phosphatase (STEP) for Alzheimer’s Disease Therapeutics.
Alzheimers Dement
December 2024
Sanford burnham prebys medical discovery institute, San Diego, CA, USA
Background: A pathological hallmark of Alzheimer’s disease (AD) is the accumulation of amyloid‐beta peptide (Aß). Potential treatments targeting Aß production such as γ‐secretase inhibitors have had limited success. A promising alternative approach involves addressing early synaptic dysfunction by modulating molecules like striatal‐enriched protein tyrosine phosphatase (STEP), whose levels and activity are upregulated by Aß.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!